EXO1 and central nervous system cancer: Previous studies have shown that EXO1 is associated with the poor prognosis of patients with breast cancer (Muthuswami et al., 2013), invasive ductal carcinoma (Kretschmer et al., 2011), and gliomas (de Sousa et al., 2017).